Seeking Alpha

Endo International plc (ENDP)

  • May. 13, 2013, 12:20 PM
    Endo Health Solutions (ENDP -2.6%) appears to have stabilized today, albeit lower, following a couple of trading halts on volatility just prior to Friday's close after the FDA denied its petition to halt generic competition to its painkiller Opana ER on safety grounds. The ruling will mean a big hit to earnings next quarter, and likely lead exploring options to mitigate the damage. Jefferies says the FDA was wrong, and acted "irrationally inconsistent" in its decision. Nonetheless, the firm lowers its price target on the shares from $47.00 to $37.00.
    | Comment!
  • May. 10, 2013, 5:47 PM
    After-hours top gainers, as of 5:30 p.m.: ENDP +3.6%. NVAX +2.8%. GRFS +2.7%. REE +2.6%. IMRS +2.4%.
    AftTer-hours top losers: ET -4.0%. APTS -3.7%. SYNC -3.6%. SSRI -2.7%. VG -2.5%.
    | Comment!
  • May. 10, 2013, 4:15 PM
    Today's decision by the FDA on Endo's (ENDP -5.3%) Opana ER puts to rest an aggressive campaign begun last October by the drug developer to keep generic versions off the market. In the end, the agency comes full circle, reiterating that the original formulation of Opana ER was not withdrawn for reasons of safety or effectiveness. Therefore, generic versions of the original formulation can continue to be approved and marketed. Following a brief resumption of trading just before the closing bell, the stock has since been halted a second time.
    | Comment!
  • May. 10, 2013, 3:36 PM
    Shares of Endo Health (ENDP -3.6%) trade lower following a brief halt after the FDA denies its petition to block generic versions of its Opana ER. ZGNX +2.1%, IPXL +8.4%.
    | Comment!
  • Apr. 16, 2013, 7:34 PM
    Endo Health Solutions (ENDP) trades higher after hours as the FDA says it won't approve generic copies of the old version of OxyContin. The first patent on the old version expired today, and drug makers had been lining up to make copies. But the newer, reformulated OxyContin was found to be tougher to crush, break or dissolve, the FDA said, and "the benefits of the old formulation no longer outweigh its risks." Shares +5.6% AH.
    | Comment!
  • Apr. 16, 2013, 5:30 PM
    After-hours top gainers, as of 5:15 p.m.: BPFH +14%. VXZ +9%. ENDP +6%. NMR +3%. HL +2%.
    After-hours top losers: PNFP -11%. QNST -8%. URI -4%. TMO -4%. YHOO -4%.
    | Comment!
  • Feb. 25, 2013, 11:34 AM
    Endo Health Solutions (ENDP +7.1%) names Rajiv De Silva , who had been president of Valeant Pharmaceuticals International (VRX +0.6%), as it's president and CEO, effective March 18. De Silva, who will also join the Endo board of directors, succeeds its retiring current CEO David Holveck. The announcement eclipses a downgrade by Jefferies to Underweight, citing persistent uncertainty over the extent of generic competition on Opana ER and Lidoderm.
    | Comment!
  • Jan. 31, 2013, 4:58 AM
    Endo Health (ENDP) closed +10.8% yesterday following a report that it has held buyout discussions with potential suitors such as Warner Chilcott (WCRX) and Valeant (VRX). Endo, which is looking for a CEO and has a market cap of $3.6B, is not holding an official auction process at the moment.
    | Comment!
  • Jan. 30, 2013, 2:38 PM
    Endo Pharmaceutical (ENDP) resumes trading, now up over 12%.
    | Comment!
  • Jan. 30, 2013, 2:34 PM
    Shares of Endo Pharmaceutical (ENDP +6.7%) have been halted due to volatility after spiking 6% higher in a matter of minutes.
    | 1 Comment
  • Jan. 4, 2013, 10:53 AM
    Endo Health Solutions (ENDP -4.5%) trades lower after cutting its 2013 guidance yesterday due to higher charges related to its core painkiller franchise and generic-drug business. It now expects its EPS to be within a range of $4.40 to $4.70 a share, down from earlier projections of $5.20 to $5.40. Revenue is projected between $2.8B to $2.95B, below previous estimates of $3B to $3.2B. Piper Jaffray cut the shares to Neutral on the news, and lowers its price target to $28.
    | Comment!
  • Dec. 19, 2012, 5:21 PM
    Endo Health (ENDP) says the U.S. District Court has ruled against its bid to stop sales of generic versions of its painkiller Opana ER, saying the FDA has not unduly delayed making a determination on the matter as to whether the original formulation was withdrawn from the market for reasons of safety. The ruling now allows for a generic non-tamper resistant version to enter the market in January, 2013. Shares -3.6% AH.
    | Comment!
  • Dec. 14, 2012, 12:17 PM
    Endo Health Solutions (ENDP -2.1%) slips today after Needham cut the shares to Underperform on the back of yesterday's earnings warning. The firm notes that a dead-cat bounce stock may be possible at current levels, but there's little upside remaining due to its "continued deterioration in core franchises, execution missteps and underwhelming operating performance in acquired non-pharma segments."
    | Comment!
  • Dec. 12, 2012, 5:47 PM
    Endo Health (ENDP) pulls its 2013 guidance, saying it no longer expects to hit its EPS target of between $5.20 - $5.40 on revenues of $3.0B - $3.2B. The company says it will provide updated 2013 guidance in early January. Street consensus estimates are for an EPS of $5.21 on revenue of $3.08B. Additionally, the company says that CEO David P. Holveck, will retire in 2013. Shares -7.3% AH.
    | Comment!
  • Nov. 15, 2012, 3:23 PM
    Notes from Endo Health's (ENDP +4.3%) presentation at Credit Suisse's annual Healthcare Conference: Reaffirms FY12 outlook given on November 5, sees Q4 EPS $1.58 - $1.68, at the high range of Street consensus at $1.60. Peak sales in Opana ER are expected to be in excess of $800M. (Webcast)
    | Comment!
  • May. 29, 2012, 9:54 AM
    Endo Health (ENDP +4.8%) settles two patent lawsuits with Watson Pharmaceuticals (WPI +1.8%) that will allow the latter to launch a generic version of Lidoderm, Endo's $1B+ pain-relieving patch, from September 2013, pending FDA approval. Watson will pay Endo a quarter of the gross profit as royalty.
    | Comment!
ENDP vs. ETF Alternatives
Company Description
Endo International PLC is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices.